These companies will be affected by new Jardiance-data
According to pan-Nordic bank Nordea, Novo Nordisk is not the company set to take the biggest hit from new remarkable data for Eli Lilly and Boehringer Ingelheim’s oral diabetes drug Jardiance.
BY ELIZABETH MØNSTED JOHANSEN
Eli Lilly presented remarkable data for its oral diabetes drug Jardiance, developed with Germany’s Boehringer Ingelheim, this week at the 51st Annual Meeting of The European Association for the Study of Diabetes in Stockholm, Sweden.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Rival data could increase pressure on Novo
For abonnenter
Analyst: Novo’s product is superior, but…
For abonnenter
Novo Nordisk affected by pricing pressure in the US
For abonnenter
